InspireMD, Inc.
NSPRNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $9.0M | $7.0M | $6.2M | $5.2M | $4.5M | $2.5M |
| Operating income | −$49.6M | −$33.5M | −$21.1M | −$18.7M | −$14.7M | −$10.4M |
| Net income | −$48.8M | −$32.0M | −$19.9M | −$18.5M | −$14.9M | −$10.5M |
| Total assets | $69.4M | $46.8M | $47.6M | $24.7M | $39.7M | $17.8M |
| Total liabilities | $14.2M | $10.7M | $8.1M | $7.3M | $6.2M | $5.6M |
| Equity | $55.2M | $36.1M | $39.5M | $17.4M | $33.5M | $12.2M |
| EPS (diluted) | $-0.76 | $-0.76 | $-0.82 | $-2.35 | $-2.03 | — |
| Shares out. | 29.7M | 23.5M | 8.3M | 8.3M | 117.8M | 4.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −552.6%
- Net margin
- −543.3%
- Return on equity
- −88.4%
- Return on assets
- −70.3%
- Return on capital (ROCE)
- −84.5%
- Liabilities / assets
- 20.5%
- Debt / equity
- 0.26×
- Book value / share
- $1.86
- Revenue growth (YoY)
- 28.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -10.12distress
- Accruals / assets
- −19.7%clean
- Beneish M-Score
- -3.30normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Nantahala Capital Management, LlcPassive (13G)May 15, 2026
- Velan Capital Investment Management LpPassive (13G)May 15, 2026
- Slosman MarvinActivist (13D)Apr 24, 2026
- Orbimed Advisors LlcPassive (13G)Feb 17, 2026
- Rosalind Advisors, Inc.Passive (13G)Feb 11, 2026
- Aberdeen Group PlcPassive (13G)Feb 2, 2026
- Nantahala Capital Partners Limited PartnershipPassive (13G)Nov 14, 2025
- Parkman Healthcare Partners LlcPassive (13G)Nov 14, 2025
- Marshall Wace, LlpPassive (13G)Nov 14, 2025
- Shore CraigActivist (13D)Oct 29, 2025
- Lawless Michael AActivist (13D)Oct 29, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Stuka PaulDirector | May 27, 2026 | Buy | 20,000 | $0.88 |
| Gleason Shane ThomasOfficer — Chief Commercial Officer | Jan 27, 2025 | Sell | 3,858 | $2.71 |
| Stuka PaulDirector | May 13, 2026 | Buy | 10,000 | $1.16 |
| Slosman MarvinOfficer — CEO and President | May 12, 2026 | Buy | 21,000 | $1.20 |
| Stuka PaulDirector | May 8, 2026 | Buy | 65,626 | $1.16 |
| Ward Scott R.Director | May 6, 2026 | Buy | 15,995 | $1.15 |
| Stuka PaulDirector | May 6, 2026 | Buy | 1,517 | $1.12 |
| Roubin Gary SDirector | May 7, 2026 | Buy | 90,000 | $1.18 |
| Gleason Shane ThomasOfficer — Chief Commercial Officer | Jan 15, 2026 | Sell | 2,909 | $1.58 |
| Ward Scott R.Director | Jan 14, 2026 | Grant | 88,053 | $0.00 |
| Tommasoli AndreaOfficer — Chief Operating Officer | Jan 14, 2026 | Grant | 226,695 | $0.00 |
| Stuka PaulDirector | Jan 14, 2026 | Grant | 132,076 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 35,122 | 1.0 | -16.4% |
| Apr 30, 2026 | 42,009 | 1.0 | +46.1% |
| Apr 15, 2026 | 28,756 | 1.0 | +5.2% |
| Mar 31, 2026 | 27,323 | 1.0 | +35.1% |
| Mar 13, 2026 | 20,223 | 1.0 | -36.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 22, 2026
- Results of operationsMay 4, 2026
- Regulation FD disclosure · Other material eventMay 1, 2026
- Entered a material agreement · Other material eventApr 3, 2026
- Results of operations · Regulation FD disclosureMar 18, 2026
- Director / officer changeMar 4, 2026
- Director / officer changeDec 19, 2025
- Results of operations · Regulation FD disclosureNov 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.